PMID: 9423839Jan 10, 1998Paper

Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice

Infection and Immunity
M M GozarD Kaslow

Abstract

Transmission-blocking vaccines based on sexual-stage surface antigens of Plasmodium falciparum may assist in the control of this lethal form of human malaria. Two vaccine candidates, Pfs25 and Pfs28, were produced as single recombinant fusion proteins. The 39-kDa chimeric proteins, having a C-terminal His6 tag, were secreted by Saccharomyces cerevisiae, using the prepro-alpha-factor leader sequence. Pfs25-28 fusion proteins were significantly more potent than either Pfs25 or Pfs28 alone in eliciting antibodies in mice that blocked oocyst development in Anopheles freeborni mosquitoes: complete inhibition of oocyst development in the mosquito midgut was achieved with fewer vaccinations, at a lower dose, and for a longer duration than with either Pfs25 or Pfs28 alone. Increased antigen-specific immunoglobulin G titers and highly significant lymphoproliferative stimulation by Pfs28-containing antigens suggest the presence of an immunodominant helper T-cell epitope in the Pfs28 portion of the fusion proteins. This epitope may be responsible for the enhanced humoral response to both Pfs25 and Pfs28 antigens. Protein production of the fusion protein was improved 12-fold by converting Pfs28 codons to yeast-preferred codons (TBV28), usi...Continue Reading

References

May 15, 1987·Analytical Biochemistry·D J O'ShannessyR H Quarles
Dec 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·K Struhl
Aug 1, 1993·Current Opinion in Immunology·D C Kaslow
Feb 1, 1997·International Journal for Parasitology·D C Kaslow

❮ Previous
Next ❯

Citations

Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·J M VinetzD A Fidock
Dec 1, 2001·Expert Opinion on Biological Therapy·A Stowers, R Carter
Sep 30, 2005·Biotechnology and Bioengineering·Isabel AndrésJesús Zueco
May 23, 2012·PloS One·James A GregoryStephen Mayfield
Jan 20, 2015·Expert Review of Vaccines·Daria NikolaevaSumi Biswas
Jan 6, 2015·The Journal of Pharmacy and Pharmacology·Roslyn M Bill
Dec 17, 2019·Immunological Reviews·Roos M de JongTeun Bousema
Apr 23, 2013·Applied and Environmental Microbiology·James A GregoryStephen Mayfield
Jan 30, 2020·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·B Gunasekaran, K M Gothandam
Sep 1, 2007·Current Opinion in Infectious Diseases·Allan Saul
Aug 30, 2019·Nature Reviews. Immunology·Jean-Philippe Julien, Hedda Wardemann
Mar 9, 2010·Memórias do Instituto Oswaldo Cruz·Iliano V Coutinho-Abreu, Marcelo Ramalho-Ortigao
Jun 18, 2010·Clinical and Vaccine Immunology : CVI·Sung-Ung MoonHyeong-Woo Lee
Nov 18, 2005·The American Journal of Tropical Medicine and Hygiene·Myriam Arévalo-HerreraSócrates Herrera
Feb 7, 2018·Frontiers in Immunology·Vinay MenonSumi Biswas
Jan 23, 2019·FEMS Yeast Research·Ravinder Kumar, Piyush Kumar
Apr 2, 2021·Probiotics and Antimicrobial Proteins·Timothy BamgboseJosé de la Fuente
Apr 27, 2000·Parasitology Today·A GhoshM Jacobs-Lorena
Nov 9, 2000·Molecular and Biochemical Parasitology·D TaylorA Saul
Jan 25, 2003·Parasitology International·Takafumi TsuboiMotomi Torii
Aug 4, 2006·Archives of Biochemistry and Biophysics·W TanL M C Chow

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.